Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
The Berlin biotech company MOLOGEN AG has had good results so far in
a clinical study with the cancer drug MGN1703. The safety and
efficacy of MGN1703 are currently under investigation in a phase I
trial.
MGN1703 has demonstrated a favorable safety profile and good
tolerability thus far. The dosing regimen specified in the study plan
could therefore be followed without modification.
Patients were initially treated with single doses of the drug. Based
on good tolerability, when the single treatment was over, all
patients were switched to a higher dose involving multiple
administrations for a longer period. Currently the last patient group
is going to be included and will be treated according to the highest
dosing regimen planned.
Assuming the trial continues to proceed according to plan, MOLOGEN
expects to finish the treatments at the end of the first quarter of
2009.
In consideration of the favorable progress and imminent completion of
the study, MOLOGEN is currently intensively engaged in preparing
additional clinical trials investigating the efficacy of MGN1703
(phase II).
Dr. Matthias Schroff, CEO of MOLOGEN AG, said: "We are extremely
pleased with the progress of the study so far and the safety profile
of MGN1703. When the current treatments are finished, we want to
start additional studies on MGN1703 as soon as possible in order to
investigate the drug's efficacy potential in the treatment of various
cancers."
Information about the clinical study with MGN1703
The study (Phase I) of the safety, compatibility and immunological
effect of MGN1703 in the treatment of various cancers is a major
milestone for a comprehensive clinical development program. The study
is currently performed at the renowned cancer centers in university
hospitals in Essen and Cologne. MOLOGEN plans to establish an
effective, compatible treatment for the treatment of the most
frequent cancers in the form of MGN1703.
dSLIM® - an innovative TLR9 agonist
In dSLIM® ("double Stem Loop Immunomodulator"), MOLOGEN has developed
an innovative TLR9 agonist. Use of dSLIM® activates the immune system
against tumor-associated antigens by targeting the different
receptors, primarily TLR9, on certain immune cells. As a result of
chemotherapy and radiotherapy, tumor-associated antigens (TAA) are
released by cancer cells. The immune system activated by dSLIM® is in
a position to overcome its fatal tolerance towards cancer cells and
TAA and advance against them strategically.
About MOLOGEN
MOLOGEN AG, a biopharmaceutical company based in Berlin, specializes
in the research and development of innovative medicines based on DNA
structures (DNA: deoxyribonucleic acid).
Its patented DNA-based technology platforms MIDGE® and dSLIM® form a
universal foundation with a wide range of possible applications.
Activities focus on product developments for the treatment of cancer
and vaccines for serious infections in humans and animals.
MOLOGEN was founded in 1998 and was the first German biotechnology
company to go public. MOLOGEN AG shares are listed in the General
Standard of Deutsche Börse (ISIN DE 0006637200).
Disclaimer concerning prognoses
Certain statements in this communication contain formulations or
terms referring to the future or future developments, as well as
negations of such formulations or terms, or similar terminology.
These are described as forward-looking statements. In addition, all
information in this communication regarding planned or future results
of business segments, financial classification numbers, developments
of the financial situation, or other financial or statistical data
contains such forward-looking statements. The company cautions
prospective investors not to rely on such forward-looking statements
as certain prognoses of actual future events and developments. The
company is neither responsible nor liable for these forward-looking
statements. It is not responsible for updating such information,
which only represents the state of affairs on the day of publication.
MOLOGEN AG
Fabeckstr. 30, 14195 Berlin, Germany
Contact: Joerg Petrass
Email: investor@mologen.com
Phone: +49-30-84 17 88-13
Fax: +49-30-84 17 88-50
--- End of Message ---
MOLOGEN AG
Fabeckstr. 30 Berlin Germany
WKN: 663720; ISIN:
DE0006637200;
Listed: Freiverkehr in Börse Berlin, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
General Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Stuttgart;
Copyright © Hugin AS 2009. All rights reserved.